Effect of smoking and transdermal nicotine on colonic nicotinic acetylcholine receptors in ulcerative colitis

QJM: An International Journal of Medicine

Volumn 96, Issue 1, 2003, Pages 57-66

  Richardson, C E ^a   Morgan, J M ^a   Jasani, B ^a   Green, J T ^a   Rhodes, John ^a   Williams, G T ^a   Lindstrom, J ^b   Wonnacott, S ^c   Peel, S ^d   Thomas, G A O ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of Bath   (United Kingdom)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; NICOTINE; NICOTINIC RECEPTOR; PLACEBO; RECEPTOR SUBUNIT;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CELL METABOLISM; CLINICAL ARTICLE; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG MECHANISM; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; INTESTINE WALL; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECEPTOR DENSITY; RECTUM BIOPSY; RECTUM MUCOSA; SMOKING; TRANSDERMAL PATCH; ULCERATIVE COLITIS;

EID: 0037257090     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/96.1.57     Document Type: Article

References (35)

1. Harries AD, Baird A, Rhodes J. Non smoking: a feature of ulcerative colitis. Br Med J 1982; 284:706.
2. Lidberg E, Tysk C, Andersson K, Jarnerot G. Smoking and inflammatory bowel disease: a case-control study. Gut 1988; 29:352-7.
3. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34:1841-54.
4. Green JT, Rhodes J, Ragunath K, Thomas GAO, Williams GT, Mani V, Feyerabend C, Russell MAH. Clinical studies of ulcerative colitis in patients who smoke. Am J Gastroenterol 1998; 93:1463-7.
5. Rudra T, Motley R, Rhodes J. Does smoking improve colitis? Scand J Gastroenterol 1989; 170(Suppl.):61-3.
6. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MAH, Feyerabend G, Thomas GAO, Sawe U. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330:811-15.
7. Sandborn WJ, Tremaine W, Offord KP, et al. Transdermal nicotine for mildly to moderately active ulcerative colitis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126:364-71.
8. Finnie IA, Campbell BJ, Taylor BA, Milton JD, Sadek JD, Yu LG, Rhodes JM. Stimulation of colonic mucin synthesis by corticosteroids and nicotine. Clin Sci 1996; 91:359-64.
9. Green JT, Richardson C, Marshall RW, Rhodes J, McKirdy H, Thomas GA, Williams GT. Nitric oxide mediates a therapeutic effect of nicotine in ulcerative colitis. Aliment Pharmacol Ther 2000; 14:1429-34.
10. Holt PG. Immune and inflammatory function in cigarette smokers. Thorax 1987; 8:381-91.
11. Miller LG, Goldstein G, Murphy M, Ginns LC. Reversible alterations in immunoregulatory T cells in smoking. Chest 1982; 5:527-9.
12. Richardson CE, Morgan JM, Jasani B, Green JT, Rhodes J, Williams GT, Lindstrom J, Wonnacott S, Thomas GAO, Smith V. Megacystis-Microcolon-IntestinaI Hypoperistalsis Syndrome (MMIHS) is associated with absence of the α3 nicotinic acetylcholine receptor subunit. Gastroenterology 2001; 121:350-7.
13. Lindstrom J. Acetylcholine receptors and myasthenia. Muscle Nerve 2000; 23:453-71.
14. Lustig LR, Peng H, Hiel H, Yamamoto T, Fuchs PA. Molecular cloning and mapping of the human nicotinic acetylcholine receptor alpha10 (CHRNA 10). Genomics 2001; 73:272-83.
15. Unwin N. Nicotinic acetylcholine receptor at 9A resolution. J Mol Biol 1993; 229:1101-24.
16. Unwin N. Acetylcholine receptor channel imaged in the open state. Nature 1995; 373:37-43.
17. Wang F, Gerzanich V, Wells GB, Anand R, Peng X, Keyser K, Lindstrom J. Assembly of human neuronal nicotinic receptor α5 subunits with α3, β2 and β4 subunits. J Biol Chem 1996; 271:17656-65.
18. Grando SA, Horton RM, Pereira EF, Diethelm-Okita BM, George PM, Albuquerque EX, Conti-Fine BM. A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes. J Invest Dermatol 1995; 105:774-81.
19. Zia S, Ndoye A, Nguyen VT, Grando SA. Nicotine enhances expression of the α3, α4, α5 and α7 nicotinic receptors modulating calcium metabolism and regulating adhesion and motility of respiratory epithelial cells. Res Commun Mol Pathol Pharmacol 1997; 97:243-62.
20. Peng X, Gerzanich V, Anand R, Wang F, Lindstrom J, et al. Chronic nicotine treatment up-regulates α3 AChRs and α7 AChRs expressed by the human neuroblastoma cell line SH-SY5Y. Mol Pharmacol 1997; 45:546-54.
21. Ridley DL, Rogers A, Wonnacott S. Differential effects of chronic drug treatment on α3 and α7 nicotinic receptor binding sites, in hippocampal neurones and SH-SY5Y cells. Br J Pharmacol 2001; 133:1286-95.
22. Peng X, Anand R, Whiting P, Lindstrom J. Nicotine induced upregulation of neuronal nicotinic receptors results from a decrease in the rate of turnover. Mol Pharmacol 1994; 46:523-30.
23. Olale F, Gerzanich V, Kuryatov A, Wang F, Lindstrom J. Chronic nicotine exposure differentially affects the function of human α3, α5 and α7 neuronal nicotinic receptor subtypes. J Pharmacol Exp Ther 1997; 283:675-83.
24. Thomas GAO, Rhodes J, Mani V, Williams GT, Newcombe RG, Russell MAH, Feyerabend C. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995; 332:988-92.
25. Lindstrom J. Monoclonal antibodies to nicotinic acetylcholine receptors. Neurotransmissions 1996; 12:1-9.
26. Truelove SC, Richards WCD. Biopsy studies in ulcerative colitis. Br Med J 1956; 2:1315-21.
27. Benowitz NL, Kuyt F, Jacob P III, Jones RT, Osmann AL. Cotinine disposition and effects. Clin Pharmacol Ther 1983; 34:604-6.
28. Grando SA, Crosby AM, Zelickson BD, Dahl MV. Agarose gel keratinocyte outgrowth system as a model of skin re-epithelization: requirement of endogenous acetylcholine for outgrowth migration. J Invest Dermatol 1993; 101:804-10.
29. Grando SA, Horton RM, Mauro TM, Kist DA, Lee TX, Dahl MV. Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation. J Invest Dermatol 1996; 107:412-18.
30. Badio B, Daly J. Epibatidine, a potent analgesic and nicotinic agonist. Mol Pharmacol 1994; 45:563-569.
31. Gerzanich V, Peng X, Wang F, Wells G. Anand R, Fletcher S, Lindstrom J. Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol 1995; 48:774-82.
32. Green JT, Peel S, Wonnacott S, Jasani B, Williams GT, Thomas GAO, Rhodes J. Demonstration of nicotinic acetylcholine receptors in human colon. Digestion 1998; 59:696.
33. Allan A, Bristol JB, Williamson RN. Crypt cell production rate in ulcerative procto-colitis differential increments in remission and relapse. Gut 1985; 26:999-1003.
34. Serafini EP, Kirk AP, Chambers TJ. Rate and pattern of epithelial cell proliferation in ulcerative colitis. Gut 1981; 22:648-52.
35. Gibson PR, Barkla DH. Mucosal metabolism and proliferation. In: Allan RN, Rhodes JM, Hanauer SB, eds. Inflammatory Bowel Diseases. Churchill Livingstone, 1997.